阿替洛尔在持续性非卧床腹膜透析患者中的药代动力学
Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
作者信息
Salahudeen A K, Wilkinson R, McAinsh J, Bateman D N
出版信息
Br J Clin Pharmacol. 1984 Sep;18(3):457-60. doi: 10.1111/j.1365-2125.1984.tb02490.x.
Abstract
The elimination of atenolol (20 mg i.v.) has been studied in seven patients with renal failure on continuous ambulatory peritoneal dialysis (CAPD). Although atenolol was eliminated in the peritoneal fluid, the amount recovered in 24 h was relatively low (1.2 +/- 0.15 mg). The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/- 0.058 l/h and 0.152 +/- 0.018 l/h respectively. This was considerably less than calculated total body clearance (1.21 +/- 0.086 l/h). The kinetics of atenolol in CAPD are worthy of further study.
摘要
对7例持续非卧床腹膜透析（CAPD）的肾衰竭患者进行了阿替洛尔（静脉注射20毫克）消除情况的研究。尽管阿替洛尔可在腹膜液中消除，但24小时内回收的量相对较低（1.2±0.15毫克）。计算得出的尿清除率（n = 4）和腹膜清除率（n = 7）分别为0.289±0.058升/小时和0.152±0.018升/小时。这远低于计算得出的总体清除率（1.21±0.086升/小时）。阿替洛尔在CAPD中的药代动力学值得进一步研究。
相似文献
1
Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
Br J Clin Pharmacol. 1984 Sep;18(3):457-60. doi: 10.1111/j.1365-2125.1984.tb02490.x.
2
Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.
Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):41-8. doi: 10.1007/BF03189860.
3
Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
Br J Clin Pharmacol. 1985 Feb;19(2):211-7. doi: 10.1111/j.1365-2125.1985.tb02633.x.
4
Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
Clin Exp Dial Apheresis. 1981;5(4):391-7. doi: 10.3109/08860228109076030.
5
Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):501-4. doi: 10.1007/BF00613532.
6
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
7
Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis.
Am J Kidney Dis. 1986 Jun;7(6):507-10. doi: 10.1016/s0272-6386(86)80193-7.
8
9
Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.
Br J Clin Pharmacol. 1988 Jun;25(6):761-5. doi: 10.1111/j.1365-2125.1988.tb05265.x.
10
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1985 Sep;38(3):285-9. doi: 10.1038/clpt.1985.172.
引用本文的文献
1
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.
Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7.
2
Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.
Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):41-8. doi: 10.1007/BF03189860.
3
Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.
Br J Clin Pharmacol. 1988 Jun;25(6):761-5. doi: 10.1111/j.1365-2125.1988.tb05265.x.
4
Teicoplanin pharmacokinetics in patients with chronic renal failure.
Clin Pharmacokinet. 1987 Apr;12(4):292-301. doi: 10.2165/00003088-198712040-00003.
5
Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):501-4. doi: 10.1007/BF00613532.
6
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007.
本文引用的文献
1
Atenolol kinetics in renal failure.
Clin Pharmacol Ther. 1980 Sep;28(3):302-9. doi: 10.1038/clpt.1980.166.
2
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
3
The pharmacokinetics of single doses of metoclopramide in renal failure.
Eur J Clin Pharmacol. 1981;19(6):437-41. doi: 10.1007/BF00548588.
4
Kinetics and absolute bioavailability of atenolol.
Clin Pharmacol Ther. 1979 Apr;25(4):408-15. doi: 10.1002/cpt1979254408.
5
The gas chromatographic determination of atenolol in biological samples.
J Pharm Pharmacol. 1975 Jun;27(6):430-3. doi: 10.1111/j.2042-7158.1975.tb09473.x.
6
Metabolism of atenolol in man.
Xenobiotica. 1978 May;8(5):313-20. doi: 10.3109/00498257809060956.
Zotero 插件